BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Huang G, Lau WY, Wang ZG, Pan ZY, Yuan SX, Shen F, Zhou WP, Wu MC. Antiviral therapy improves postoperative survival in patients with hepatocellular carcinoma: a randomized controlled trial. Ann Surg. 2015;261:56-66. [PMID: 25072444 DOI: 10.1097/sla.0000000000000858] [Cited by in Crossref: 129] [Cited by in F6Publishing: 149] [Article Influence: 18.4] [Reference Citation Analysis]
Number Citing Articles
1 Li Z, Tan C, Liu X, Feng Z, Li K. Early and late recurrence after hepatectomy in patients with low-level HBV-DNA hepatocellular carcinoma under antiviral therapy. Infect Agents Cancer 2022;17:56. [DOI: 10.1186/s13027-022-00468-6] [Reference Citation Analysis]
2 Nevarez NM, Chang GY, Yopp AC. An Overview of Clinical Trials in the Treatment of Resectable Hepatocellular Carcinoma. Surgical Oncology Clinics of North America 2022. [DOI: 10.1016/j.soc.2022.07.008] [Reference Citation Analysis]
3 Zeng ZM, Mo N, Zeng J, Ma FC, Jiang YF, Huang HS, Liao XW, Zhu GZ, Ma J, Peng T. Advances in postoperative adjuvant therapy for primary liver cancer. World J Gastrointest Oncol 2022; 14(9): 1604-1621 [DOI: 10.4251/wjgo.v14.i9.1604] [Reference Citation Analysis]
4 Gong L, Pan L. Comment on "Predictors of changes in preoperative tumor stage between dynamic computed tomography and gadoxetate disodium-enhanced magnetic resonance imaging for hepatocellular carcinoma". J Formos Med Assoc 2022:S0929-6646(22)00290-X. [PMID: 35999157 DOI: 10.1016/j.jfma.2022.08.003] [Reference Citation Analysis]
5 Liu H, Yang XL, Dong ZR, Chen ZQ, Hong JG, Wang DX, Li T. Clinical benefits of direct-acting antivirals therapy in hepatitis C virus patients with hepatocellular carcinoma: A systematic review and meta-analysis. J Gastroenterol Hepatol 2022. [PMID: 35722709 DOI: 10.1111/jgh.15915] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Feng Y, Zhao Y, Li W, He X, Zhou C, Pan Q, Mao A, Zhu W, Hu C, Wang L. Hepatic resection prolongs overall survival in the selected patients with nasopharyngeal carcinoma liver metastases. European Journal of Surgical Oncology 2022. [DOI: 10.1016/j.ejso.2022.05.033] [Reference Citation Analysis]
7 Jethwa KR, Hallemeier CL. Hepatobiliary Cancers. Principles and Practice of Particle Therapy 2022. [DOI: 10.1002/9781119707530.ch19] [Reference Citation Analysis]
8 Pang S, Shi Y, Xu D, Sun Z, Chen Y, Yang Y, Zhao X, Si-Ma H, Yang N. Screening of Hepatocellular Carcinoma Patients with High Risk of Early Recurrence After Radical Hepatectomy Using a Nomogram Model Based on the γ-Glutamyl Transpeptidase-to-Albumin Ratio. J Gastrointest Surg 2022. [PMID: 35508683 DOI: 10.1007/s11605-022-05326-9] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Yoo S, Kim JY, Lim Y, Han S, Choi J. Impact of HBsAg seroclearance on late recurrence of hepatitis B virus–related hepatocellular carcinoma after surgical resection. Journal of Hepatology 2022. [DOI: 10.1016/j.jhep.2022.05.014] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
10 Sun HC, Zhou J, Wang Z, Liu X, Xie Q, Jia W, Zhao M, Bi X, Li G, Bai X, Ji Y, Xu L, Zhu XD, Bai D, Chen Y, Chen Y, Dai C, Guo R, Guo W, Hao C, Huang T, Huang Z, Li D, Li G, Li T, Li X, Li G, Liang X, Liu J, Liu F, Lu S, Lu Z, Lv W, Mao Y, Shao G, Shi Y, Song T, Tan G, Tang Y, Tao K, Wan C, Wang G, Wang L, Wang S, Wen T, Xing B, Xiang B, Yan S, Yang D, Yin G, Yin T, Yin Z, Yu Z, Zhang B, Zhang J, Zhang S, Zhang T, Zhang Y, Zhang Y, Zhang A, Zhao H, Zhou L, Zhang W, Zhu Z, Qin S, Shen F, Cai X, Teng G, Cai J, Chen M, Li Q, Liu L, Wang W, Liang T, Dong J, Chen X, Wang X, Zheng S, Fan J; Alliance of Liver Cancer Conversion Therapy, Committee of Liver Cancer of the Chinese Anti-Cancer Association. Chinese expert consensus on conversion therapy for hepatocellular carcinoma (2021 edition). Hepatobiliary Surg Nutr 2022;11:227-52. [PMID: 35464283 DOI: 10.21037/hbsn-21-328] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
11 Takaura K, Kurosaki M, Inada K, Kirino S, Yamashita K, Muto T, Osawa L, Sekiguchi S, Hayakawa Y, Higuchi M, Kaneko S, Maeyashiki C, Tamaki N, Yasui Y, Itakura J, Tsuchiya K, Nakanishi H, Takahashi Y, Izumi N. The impact of background liver disease on the long-term prognosis of very-early-stage HCC after ablation therapy. PLoS ONE 2022;17:e0264075. [DOI: 10.1371/journal.pone.0264075] [Reference Citation Analysis]
12 Wang X, Hu Z, Fu Y, Hou J, Li W, Zhang Y, Xu L, Zhou Q, Chen M, Zhou Z. Tenofovir vs. entecavir on prognosis of hepatitis B virus-related hepatocellular carcinoma after curative resection. J Gastroenterol. [DOI: 10.1007/s00535-022-01855-x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
13 Guo X, Zhang W, Du J, Tao R, Dong W, Huang J, Zhang J, Pan Z, Zhou W, Zhu X, Liu H, Liu F. Acute-Phase Serum Amyloid A May Predict Microvascular Invasion and Early Tumor Recurrence in Patients with Hepatitis B Virus-Related Hepatocellular Carcinoma Undergoing Liver Resection. J Invest Surg 2022;:1-9. [PMID: 35143736 DOI: 10.1080/08941939.2022.2035858] [Reference Citation Analysis]
14 Galun D, Mijac D, Filipovic A, Bogdanovic A, Zivanovic M, Masulovic D. Precision Medicine for Hepatocellular Carcinoma: Clinical Perspective. JPM 2022;12:149. [DOI: 10.3390/jpm12020149] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
15 Guan R, Sun B, Wang Z, Zhou C, Yang Z, Gan W, Huang J, Liu G, Zhou J, Fan J, Yi Y, Qiu S. Antiviral therapy improves postoperative survival of patients with HBV-related hepatocellular carcinoma. The American Journal of Surgery 2022. [DOI: 10.1016/j.amjsurg.2022.01.008] [Reference Citation Analysis]
16 Korean Liver Cancer Association (KLCA) and National Cancer Center (NCC) Korea. 2022 KLCA-NCC Korea Practice Guidelines for the Management of Hepatocellular Carcinoma. Korean J Radiol 2022;23. [DOI: 10.3348/kjr.2022.0822] [Reference Citation Analysis]
17 Schemmer P, Burra P, Hu RH, Hüber CM, Loinaz C, Machida K, Vogel A, Samuel D. State of the art treatment of hepatitis B virus hepatocellular carcinoma and the role of hepatitis B surface antigen post-liver transplantation and resection. Liver Int 2021. [PMID: 34846790 DOI: 10.1111/liv.15124] [Reference Citation Analysis]
18 Hur MH, Lee JH, Kim JY, Hong JH, Park MK, Cho HJ, Choi NR, Kim J, Kim MA, Nam JY, Lee YB, Cho EJ, Yu SJ, Kim YJ, Lee DH, Lee JM, Hong SK, Yi NJ, Lee KW, Suh KS, Yoon JH. Comparison of Overall Survival between Surgical Resection and Radiofrequency Ablation for Hepatitis B-Related Hepatocellular Carcinoma. Cancers (Basel) 2021;13:6009. [PMID: 34885118 DOI: 10.3390/cancers13236009] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
19 Jin M, Chen Y, Hu S, Zhu M, Wang Y, Chen M, Peng Z. Association of Virological Response to Antiviral Therapy With Survival in Intermediate-Stage Hepatitis B Virus-Related Hepatocellular Carcinoma After Chemoembolization. Front Oncol 2021;11:751777. [PMID: 34745980 DOI: 10.3389/fonc.2021.751777] [Reference Citation Analysis]
20 Wang X, Liu X, Wang P, Yu L, Yan F, Yan H, Zhou D, Yang Z. Antiviral Therapy Reduces Mortality in Hepatocellular Carcinoma Patients with Low-Level Hepatitis B Viremia. J Hepatocell Carcinoma 2021;8:1253-67. [PMID: 34708007 DOI: 10.2147/JHC.S330301] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
21 Wang G, Duan Z. Guidelines for Prevention and Treatment of Chronic Hepatitis B. J Clin Transl Hepatol 2021;9:769-91. [PMID: 34722192 DOI: 10.14218/JCTH.2021.00209] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 9.0] [Reference Citation Analysis]
22 Xu H, Li YM, Yi Y, Zheng YW, Ohkohchi N. The Effect of the Platelet Administration for the Patients with Liver Dysfunction after Liver Resection: Preliminary Clinical Trial. Case Rep Gastrointest Med 2021;2021:9948854. [PMID: 34540297 DOI: 10.1155/2021/9948854] [Reference Citation Analysis]
23 Kong J, Liang X, Zhang J, Zeng J, Liu J, Zeng J. Antiviral Therapy Improves Survival in Hepatocellular Carcinoma with Microvascular Invasion: A Propensity Score Analysis. Dig Dis Sci 2021. [PMID: 34523084 DOI: 10.1007/s10620-021-07248-z] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
24 Teufel A, Quante M, Kandulski A, Hirth M, Zhan T, Eckardt M, Thieme R, Kusnik A, Yesmembetov K, Wiest I, Riemann JF, Schlitt HJ, Gockel I, Malfertheiner P, Ebert MP. [Prevention of gastrointestinal cancer]. Z Gastroenterol 2021;59:964-82. [PMID: 34507375 DOI: 10.1055/a-1540-7539] [Reference Citation Analysis]
25 Chen QF, Li W, Yu SC, Chou YH, Rhim H, Yang X, Shen L, Dong A, Huang T, Huang J, Zhang F, Fan W, Zhao M, Gu Y, Huang Z, Zuo M, Zhai B, Xiao Y, Kuang M, Li J, Han J, Song W, Ma J, Wu P. Consensus of Minimally Invasive and Multidisciplinary Comprehensive Treatment for Hepatocellular Carcinoma - 2020 Guangzhou Recommendations. Front Oncol 2021;11:621834. [PMID: 34277397 DOI: 10.3389/fonc.2021.621834] [Reference Citation Analysis]
26 Zhang EL, Cheng Q, Huang ZY, Dong W. Revisiting Surgical Strategies for Hepatocellular Carcinoma With Microvascular Invasion. Front Oncol 2021;11:691354. [PMID: 34123861 DOI: 10.3389/fonc.2021.691354] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 9.0] [Reference Citation Analysis]
27 Tokuyasu N, Amisaki M, Hanaki T, Murakami Y, Morimoto M, Uchinaka E, Yagyu T, Goto K, Matsunaga T, Yamamoto M, Takano S, Sakamoto T, Honjo S, Hasegawa T, Fujiwara Y. Clinical Significance of Serum Antithrombin III Activity After Hepatectomy for Hepatocellular Carcinoma. Yonago Acta Med 2021;64:168-75. [PMID: 34025191 DOI: 10.33160/yam.2021.05.007] [Reference Citation Analysis]
28 Teng W, Liu YC, Jeng WJ, Su CW. Tertiary Prevention of HCC in Chronic Hepatitis B or C Infected Patients. Cancers (Basel) 2021;13:1729. [PMID: 33917345 DOI: 10.3390/cancers13071729] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
29 Shin J, Yu JH, Jin Y, Lee J. Incidence and Clinical Features of Hepatitis C Virus-associated Hepatocellular Carcinoma Patients without Liver Cirrhosis in Hepatitis B Virus-endemic Area. J Liver Cancer 2021;21:34-44. [DOI: 10.17998/jlc.21.1.34] [Reference Citation Analysis]
30 Zhang W, Zhang B, Chen XP. Adjuvant treatment strategy after curative resection for hepatocellular carcinoma. Front Med 2021;15:155-69. [PMID: 33754281 DOI: 10.1007/s11684-021-0848-3] [Cited by in Crossref: 8] [Cited by in F6Publishing: 12] [Article Influence: 8.0] [Reference Citation Analysis]
31 Liu Y, Wang X, Xiao J, Sun J, Zhang Y. Prognostic value of postoperative change in liver stiffness in patients with HBV-related hepatocellular carcinoma. J Int Med Res 2020;48:300060520908763. [PMID: 32290747 DOI: 10.1177/0300060520908763] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
32 Liu KX, Hong JG, Wu R, Dong ZR, Yang YF, Yan YC, Yang CC, Yan LJ, Yao SY, Li HC, Zhi XT, Li T. Clinical Benefit of Antiviral Agents for Hepatocellular Carcinoma Patients With Low Preoperative HBV-DNA Loads Undergoing Curative Resection: A Meta-Analysis. Front Oncol 2021;11:605648. [PMID: 33680960 DOI: 10.3389/fonc.2021.605648] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 5.0] [Reference Citation Analysis]
33 Liu S, Lai J, Lyu N, Xie Q, Cao H, Chen D, He M, Zhang B, Zhao M. Effects of Antiviral Therapy on HBV Reactivation and Survival in Hepatocellular Carcinoma Patients Undergoing Hepatic Artery Infusion Chemotherapy. Front Oncol 2020;10:582504. [PMID: 33614477 DOI: 10.3389/fonc.2020.582504] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 7.0] [Reference Citation Analysis]
34 Choi J, Jo C, Lim YS. Tenofovir Versus Entecavir on Recurrence of Hepatitis B Virus-Related Hepatocellular Carcinoma After Surgical Resection. Hepatology 2021;73:661-73. [PMID: 32324905 DOI: 10.1002/hep.31289] [Cited by in Crossref: 32] [Cited by in F6Publishing: 35] [Article Influence: 32.0] [Reference Citation Analysis]
35 Hou J, Karin M, Sun B. Targeting cancer-promoting inflammation - have anti-inflammatory therapies come of age? Nat Rev Clin Oncol 2021;18:261-79. [PMID: 33469195 DOI: 10.1038/s41571-020-00459-9] [Cited by in Crossref: 55] [Cited by in F6Publishing: 64] [Article Influence: 55.0] [Reference Citation Analysis]
36 Kim BH, Park J. Antiviral Therapy in Liver Cancer. Radiotherapy of Liver Cancer 2021. [DOI: 10.1007/978-981-16-1815-4_5] [Reference Citation Analysis]
37 Zhou J, Sun H, Wang Z, Cong W, Wang J, Zeng M, Zhou W, Bie P, Liu L, Wen T, Han G, Wang M, Liu R, Lu L, Ren Z, Chen M, Zeng Z, Liang P, Liang C, Chen M, Yan F, Wang W, Ji Y, Yun J, Cai D, Chen Y, Cheng W, Cheng S, Dai C, Guo W, Hua B, Huang X, Jia W, Li Y, Li Y, Liang J, Liu T, Lv G, Mao Y, Peng T, Ren W, Shi H, Shi G, Tao K, Wang W, Wang X, Wang Z, Xiang B, Xing B, Xu J, Yang J, Yang J, Yang Y, Yang Y, Ye S, Yin Z, Zhang B, Zhang B, Zhang L, Zhang S, Zhang T, Zhao Y, Zheng H, Zhu J, Zhu K, Liu R, Shi Y, Xiao Y, Dai Z, Teng G, Cai J, Wang W, Cai X, Li Q, Shen F, Qin S, Dong J, Fan J. Guidelines for the Diagnosis and Treatment of Hepatocellular Carcinoma (2019 Edition). Liver Cancer 2020;9:682-720. [PMID: 33442540 DOI: 10.1159/000509424] [Cited by in Crossref: 150] [Cited by in F6Publishing: 164] [Article Influence: 75.0] [Reference Citation Analysis]
38 Liu F, Guo X, Dong W, Zhang W, Wei S, Zhang S, Zhu X, Zhou W, Zhang J, Liu H. Postoperative adjuvant TACE-associated nomogram for predicting the prognosis of resectable Hepatocellular Carcinoma with portal vein Tumor Thrombus after Liver Resection. Int J Biol Sci 2020;16:3210-20. [PMID: 33162826 DOI: 10.7150/ijbs.46896] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
39 Xie DY, Ren ZG, Zhou J, Fan J, Gao Q. 2019 Chinese clinical guidelines for the management of hepatocellular carcinoma: updates and insights. Hepatobiliary Surg Nutr. 2020;9:452-463. [PMID: 32832496 DOI: 10.21037/hbsn-20-480] [Cited by in Crossref: 118] [Cited by in F6Publishing: 132] [Article Influence: 59.0] [Reference Citation Analysis]
40 Wang Q, Yu CR. Association between liver targeted antiviral therapy in colorectal cancer and survival benefits: An appraisal. World J Clin Cases 2020; 8(11): 2111-2115 [PMID: 32548140 DOI: 10.12998/wjcc.v8.i11.2111] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
41 Zhang X, Li C, Wen T, Yan L, Yang J, Tang H, Lu C. The Different Effects of Nucleotide and Nucleoside Analogues on the Prognosis of HBV-Related HCC After Curative Resection. J Gastrointest Surg 2021;25:1419-29. [PMID: 32410175 DOI: 10.1007/s11605-020-04633-3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
42 Wang H, Yu H, Qian YW, Cao ZY, Wu MC, Cong WM. Impact of Surgical Margin on the Prognosis of Early Hepatocellular Carcinoma (≤5 cm): A Propensity Score Matching Analysis. Front Med (Lausanne) 2020;7:139. [PMID: 32478080 DOI: 10.3389/fmed.2020.00139] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 5.5] [Reference Citation Analysis]
43 Zhu XD, Li KS, Sun HC. Adjuvant therapies after curative treatments for hepatocellular carcinoma: Current status and prospects. Genes Dis 2020;7:359-69. [PMID: 32884990 DOI: 10.1016/j.gendis.2020.02.002] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 8.5] [Reference Citation Analysis]
44 Qin JM. Postoperative recurrent factors and therapeutic and preventive strategies for hepatocellular carcinoma. Shijie Huaren Xiaohua Zazhi 2019; 27(23): 1407-1418 [DOI: 10.11569/wcjd.v27.i23.1407] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
45 Wei Y, Yi Y, Tao C, Ye W, Zhao W. Impact of antiviral therapy with nucleos(t)ide analog on survival of patients with HBV-related small hepatocellular carcinomas. Cancer Manag Res 2019;11:8475-86. [PMID: 31572002 DOI: 10.2147/CMAR.S201744] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
46 Akateh C, Black SM, Conteh L, Miller ED, Noonan A, Elliott E, Pawlik TM, Tsung A, Cloyd JM. Neoadjuvant and adjuvant treatment strategies for hepatocellular carcinoma. World J Gastroenterol 2019; 25(28): 3704-3721 [PMID: 31391767 DOI: 10.3748/wjg.v25.i28.3704] [Cited by in CrossRef: 65] [Cited by in F6Publishing: 68] [Article Influence: 21.7] [Reference Citation Analysis]
47 Li YT, Wu HL, Kao JH, Cheng HR, Ho MC, Wang CC, Chen PJ, Chen DS, Liu CJ. Expression of Metastatic Tumor Antigen 1 Splice Variant Correlates With Early Recurrence and Aggressive Features of Hepatitis B Virus-Associated Hepatocellular Carcinoma. Hepatology 2019;70:184-97. [PMID: 30802976 DOI: 10.1002/hep.30581] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
48 Li ZL, Han J, Liu K, Xing H, Wu H, Lau WY, Pawlik TM, Li C, Wang MD, Yu JJ, Wu MC, Shen F, Yang T. Association of family history with long-term prognosis in patients undergoing liver resection of HBV-related hepatocellular carcinoma. Hepatobiliary Surg Nutr 2019;8:88-100. [PMID: 31098356 DOI: 10.21037/hbsn.2018.11.20] [Cited by in Crossref: 6] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
49 Huang K, Liao X, Han C, Wang X, Yu T, Yang C, Liu X, Yu L, Chen Z, Qin W, Zhu G, Su H, Liu Z, Zeng X, Zhou X, Lu S, Huang J, Liang Y, Liu Z, Deng J, Ye X, Peng T. Genetic variants and Expression of Cytochrome p450 Oxidoreductase Predict Postoperative Survival in Patients with Hepatitis B Virus-Related Hepatocellular Carcinoma. J Cancer 2019;10:1453-65. [PMID: 31031855 DOI: 10.7150/jca.28919] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
50 Takemura N, Hasegawa K, Kokudo N. Revision of Clinical Practice Guidelines for Hepatocellular Carcinoma in 2017. Acta hepatologica Japonica 2018;59:659-667. [DOI: 10.2957/kanzo.59.659] [Reference Citation Analysis]
51 Yuan H, Cao P, Li HL, Hu HT, Guo CY, Zhao Y, Yao QJ, Geng X. Transarterial chemoembolization with radiofrequency ablation versus hepatectomy in hepatocellular carcinoma beyond the Milan criteria: a retrospective study. Cancer Manag Res 2018;10:5545-52. [PMID: 30519102 DOI: 10.2147/CMAR.S182914] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
52 Chen S, Gao Y, Li Z, Jia J, Fang M, Wang M, Feng H, Chen Q, Guan W, Wang Z, Gao C. A Nomogram Predicting Extrahepatic Metastases for Patients with Adjuvant Transarterial Chemoembolization after Hepatectomy. J Cancer 2018;9:4223-33. [PMID: 30519323 DOI: 10.7150/jca.25886] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
53 Li ZL, Yan WT, Zhang J, Zhao YJ, Lau WY, Mao XH, Zeng YY, Zhou YH, Gu WM, Wang H, Chen TH, Han J, Xing H, Wu H, Li C, Wang MD, Wu MC, Shen F, Yang T. Identification of Actual 10-Year Survival After Hepatectomy of HBV-Related Hepatocellular Carcinoma: a Multicenter Study. J Gastrointest Surg 2019;23:288-96. [PMID: 30334177 DOI: 10.1007/s11605-018-4006-4] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 3.5] [Reference Citation Analysis]
54 Li Z, Lei Z, Xia Y, Li J, Wang K, Zhang H, Wan X, Yang T, Zhou W, Wu M, Pawlik TM, Lau WY, Shen F. Association of Preoperative Antiviral Treatment With Incidences of Microvascular Invasion and Early Tumor Recurrence in Hepatitis B Virus-Related Hepatocellular Carcinoma. JAMA Surg 2018;153:e182721. [PMID: 30073257 DOI: 10.1001/jamasurg.2018.2721] [Cited by in Crossref: 40] [Cited by in F6Publishing: 51] [Article Influence: 10.0] [Reference Citation Analysis]
55 Akateh C, Pawlik TM, Cloyd JM. Adjuvant antiviral therapy for the prevention of hepatocellular carcinoma recurrence after liver resection: indicated for all patients with chronic hepatitis B? Ann Transl Med. 2018;6:397. [PMID: 30498725 DOI: 10.21037/atm.2018.08.20] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
56 Xin M, Feng D, Yin B, Li Y. Efficacy of interferon therapy in patients with hepatitis B virus-related primary hepatic carcinoma after transcatheter arterial chemoembolization. Prec Radiat Oncol 2018;2:76-84. [DOI: 10.1002/pro6.53] [Reference Citation Analysis]
57 Wen T, Jin C, Facciorusso A, Donadon M, Han HS, Mao Y, Dai C, Cheng S, Zhang B, Peng B, Du S, Jia C, Xu F, Shi J, Sun J, Zhu P, Nara S, Millis JM; MDT of West China Hospital*. Multidisciplinary management of recurrent and metastatic hepatocellular carcinoma after resection: an international expert consensus. Hepatobiliary Surg Nutr 2018;7:353-71. [PMID: 30498711 DOI: 10.21037/hbsn.2018.08.01] [Cited by in Crossref: 38] [Cited by in F6Publishing: 45] [Article Influence: 9.5] [Reference Citation Analysis]
58 Orcutt ST, Anaya DA. Liver Resection and Surgical Strategies for Management of Primary Liver Cancer. Cancer Control 2018;25:1073274817744621. [PMID: 29327594 DOI: 10.1177/1073274817744621] [Cited by in Crossref: 93] [Cited by in F6Publishing: 104] [Article Influence: 23.3] [Reference Citation Analysis]
59 Zhang G, Yu X, Liu P, Huang X, Jiang X. Efficacy of Nucleoside Analogs for Chronic Hepatitis B Virus-Related Hepatocellular Carcinoma After Curative Treatment: A Meta-Analysis. Dig Dis Sci 2018;63:3207-19. [PMID: 30140982 DOI: 10.1007/s10620-018-5252-8] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
60 Wei Y, Dai F, Yi Y, Ye W, Zhao W. Impact of local tumor lesion treatments and preoperative indicators on the survival of patients with small hepatocellular carcinomas. Oncol Lett 2018;16:5050-8. [PMID: 30250572 DOI: 10.3892/ol.2018.9263] [Reference Citation Analysis]
61 Zhou J, Sun HC, Wang Z, Cong WM, Wang JH, Zeng MS, Yang JM, Bie P, Liu LX, Wen TF, Han GH, Wang MQ, Liu RB, Lu LG, Ren ZG, Chen MS, Zeng ZC, Liang P, Liang CH, Chen M, Yan FH, Wang WP, Ji Y, Cheng WW, Dai CL, Jia WD, Li YM, Li YX, Liang J, Liu TS, Lv GY, Mao YL, Ren WX, Shi HC, Wang WT, Wang XY, Xing BC, Xu JM, Yang JY, Yang YF, Ye SL, Yin ZY, Zhang BH, Zhang SJ, Zhou WP, Zhu JY, Liu R, Shi YH, Xiao YS, Dai Z, Teng GJ, Cai JQ, Wang WL, Dong JH, Li Q, Shen F, Qin SK, Fan J. Guidelines for Diagnosis and Treatment of Primary Liver Cancer in China (2017 Edition). Liver Cancer. 2018;7:235-260. [PMID: 30319983 DOI: 10.1159/000488035] [Cited by in Crossref: 286] [Cited by in F6Publishing: 326] [Article Influence: 71.5] [Reference Citation Analysis]
62 Xie YL, Chu JG, Li GX. Cryptogenic hepatocellular carcinoma (HCC) had worse overall survival of disease than viral HCC patients. Liver Int 2018;38:1140. [PMID: 29240967 DOI: 10.1111/liv.13666] [Reference Citation Analysis]
63 Yoo J, Hann HW, Coben R, Conn M, DiMarino AJ. Update Treatment for HBV Infection and Persistent Risk for Hepatocellular Carcinoma: Prospect for an HBV Cure. Diseases. 2018;6:E27. [PMID: 29677098 DOI: 10.3390/diseases6020027] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 4.8] [Reference Citation Analysis]
64 Sohn W, Kang TW, Choi SK, Jung SH, Lee MW, Lim HK, Cho JY, Shim SG, Sinn DH, Gwak GY, Choi MS, Lee JH, Koh KC, Paik SW, Rhim H, Paik YH. Effect of oral antiviral treatment on long-term outcomes of radiofrequency ablation therapy for hepatitis B virus-related hepatocellular carcinoma. Oncotarget 2016;7:47794-807. [PMID: 27329596 DOI: 10.18632/oncotarget.10026] [Cited by in Crossref: 14] [Cited by in F6Publishing: 17] [Article Influence: 3.5] [Reference Citation Analysis]
65 Ban D, Ogura T, Akahoshi K, Tanabe M. Current topics in the surgical treatments for hepatocellular carcinoma. Ann Gastroenterol Surg 2018;2:137-46. [PMID: 29863117 DOI: 10.1002/ags3.12065] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 4.3] [Reference Citation Analysis]
66 Hu H, Han XK, Long XR, Fan J, Yan ZP, Wang JH, Liu R. Prognostic nomogram for post-surgical treatment with adjuvant TACE in hepatitis B virus-related hepatocellular carcinoma. Oncotarget. 2016;7:58302-58314. [PMID: 27506942 DOI: 10.18632/oncotarget.11078] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
67 Zhang L, Xie XY, Chen Y, Ge NL, Chen RX, Gan YH, Zhang BH, Wang YH, Ren ZG. Hepatitis B surface antigen predicts recurrence after radiofrequency ablation in patients with low hepatitis B virus loads. Medicine (Baltimore) 2017;96:e9377. [PMID: 29384914 DOI: 10.1097/MD.0000000000009377] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
68 Liang B, Yao S, Zhou J, Li Z, Liu T. Liver resection versus radiofrequency ablation for hepatitis B virus-related small hepatocellular carcinoma. J Hepatocell Carcinoma 2018;5:1-7. [PMID: 29392122 DOI: 10.2147/JHC.S152202] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
69 Yan PG, Wang RY, Zhang J, Cong WM, Dong H, Yu HY, Lau WY, Wu MC, Zhou WP. Impact of Preoperative Hepatitis B Virus Levels on Prognosis After Primary and Repeat Hepatectomies for Hepatocellular Carcinoma Patients-a Retrospective Study. J Gastrointest Surg 2018;22:872-83. [PMID: 29313290 DOI: 10.1007/s11605-017-3638-0] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
70 Lee IC, Chau GY, Yeh YC, Chao Y, Huo TI, Su CW, Lin HC, Hou MC, Huang YH. Risk of recurrence in chronic hepatitis B patients developing hepatocellular carcinoma with antiviral secondary prevention failure. PLoS One 2017;12:e0188552. [PMID: 29176777 DOI: 10.1371/journal.pone.0188552] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
71 Chen XX, Cheng JW, Huang A, Zhang X, Wang J, Fan J, Zhou J, Yang XR. The effect of antiviral therapy on patients with hepatitis B virus-related hepatocellular carcinoma after curative resection: a systematic review and meta-analysis. Onco Targets Ther 2017;10:5363-75. [PMID: 29180870 DOI: 10.2147/OTT.S150281] [Cited by in Crossref: 7] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
72 Fujiwara N, Friedman SL, Goossens N, Hoshida Y. Risk factors and prevention of hepatocellular carcinoma in the era of precision medicine. J Hepatol 2018;68:526-49. [PMID: 28989095 DOI: 10.1016/j.jhep.2017.09.016] [Cited by in Crossref: 320] [Cited by in F6Publishing: 346] [Article Influence: 64.0] [Reference Citation Analysis]
73 Yuan BH, Li RH, Yuan WP, Yang T, Tong TJ, Peng NF, Li LQ, Zhong JH. Harms and benefits of adoptive immunotherapy for postoperative hepatocellular carcinoma: an updated review. Oncotarget. 2017;8:18537-18549. [PMID: 28061472 DOI: 10.18632/oncotarget.14507] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 1.4] [Reference Citation Analysis]
74 Jiang J, Hu H, Liu R, Wang JH, Long XR, Fan J, Yan ZP. Nomogram for individualized prediction of recurrence after postoperative adjuvant TACE for hepatitis B virus-related hepatocellular carcinoma. Medicine (Baltimore) 2017;96:e7390. [PMID: 28796032 DOI: 10.1097/MD.0000000000007390] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
75 Kim JH, Sinn DH, Kim K, Kim H, Gwak GY, Paik YH, Choi MS, Lee JH, Koh KC, Paik SW. Lamivudine versus Entecavir for Newly Diagnosed Hepatitis B Virus-Related Hepatocellular Carcinoma. Gut Liver 2016;10:939-47. [PMID: 27282264 DOI: 10.5009/gnl15527] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 2.4] [Reference Citation Analysis]
76 Mo HY, Liao YY, You XM, Cucchetti A, Yuan BH, Li RH, Zhong JH, Li LQ. Timely meta-analysis on the efficacy of adoptive immunotherapy for hepatocellular carcinoma patients after curative therapy. PLoS One 2017;12:e0174222. [PMID: 28339493 DOI: 10.1371/journal.pone.0174222] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
77 Yin L, Huang G, Lau WY, Zhou WP. Reply to Letter: "Adjuvant Antiviral Therapy With Nucleos(t)ide Analogs in Patients With Hepatitis B Virus--Related Hepatocellular Carcinoma". Ann Surg 2017;265:e47-8. [PMID: 28266989 DOI: 10.1097/SLA.0000000000001229] [Reference Citation Analysis]
78 Yuan BH, Li RH, Yuan WP, Xiang BD, Zheng MH, Yang T, Zhong JH, Li LQ. Perioperative entecavir for patients with HBV-related hepatocellular carcinoma and low levels of viral DNA: analysis using propensity score matching. Oncotarget 2017;8:51810-6. [PMID: 28881690 DOI: 10.18632/oncotarget.15395] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
79 Hu H, Liu R, Long XR, Han XK, Fan J, Yan ZP, Wang JH. Postsurgical treatment with adjuvant transarterial chemoembolization in patients with hepatitis B-related hepatocellular carcinoma: A strobe-compliant article. Medicine (Baltimore) 2016;95:e5517. [PMID: 28033246 DOI: 10.1097/MD.0000000000005517] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
80 Zhong JH, Ke Y, Zhu SL, Wang L, Luo CP, Gong WF, You XM, Ma L, Xiang BD, Li LQ. Adefovir dipivoxil is less expensive than lamivudine and associated with similar prognosis in patients with hepatitis B virus-related hepatocellular carcinoma after radical resection. Onco Targets Ther 2016;9:6897-907. [PMID: 27877054 DOI: 10.2147/OTT.S120062] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
81 Liao YY, Ahir BK, Mo HY, Li LQ, Peng NF. Letter: which patients with hepatitis B virus-related hepatocellular carcinoma should receive nucleos(t)ide analogue therapy? Aliment Pharmacol Ther 2016;44:908-10. [PMID: 27634236 DOI: 10.1111/apt.13773] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
82 Zhong JH, Du XK, Xiang BD, Li LQ. Adjuvant sorafenib in hepatocellular carcinoma: A cautionary comment of STORM trial. World J Hepatol 2016; 8(23): 957-960 [PMID: 27621761 DOI: 10.4254/wjh.v8.i23.957] [Cited by in Crossref: 7] [Cited by in F6Publishing: 13] [Article Influence: 1.2] [Reference Citation Analysis]
83 Xie ZB, Wang XB, Fu DL, Zhong JH, Yang XW, Li LQ. Postoperative hepatitis B virus reactivation in hepatitis B virus-related hepatocellular carcinoma patients with hepatitis B virus DNA levels <500 copies/mL. Onco Targets Ther 2016;9:4593-603. [PMID: 27524913 DOI: 10.2147/OTT.S104300] [Cited by in Crossref: 6] [Cited by in F6Publishing: 10] [Article Influence: 1.0] [Reference Citation Analysis]
84 Mo HY, Xiang BD, Zhong JH, Li LQ, You XM. Comment on "Evaluation of Antiviral Therapy Performed after Curative Therapy in Patients with HBV-Related Hepatocellular Carcinoma: An Updated Meta-Analysis". Can J Gastroenterol Hepatol 2016;2016:7625982. [PMID: 27500539 DOI: 10.1155/2016/7625982] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
85 Gong WF, Zhong JH, Xiang BD, Li LQ. Feasibility of combining adjuvant transarterial chemoembolization with nucleos(t)ide analog therapy for patients with HBV-associated hepatocellular carcinoma after hepatectomy. Mol Clin Oncol 2016;5:3-6. [PMID: 27330754 DOI: 10.3892/mco.2016.871] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
86 Li T, Wang SK, Zhi XT, Zhou J, Dong ZR, Zhang ZL, Sun HC, Ye QH, Fan J. Cholecystectomy is associated with higher risk of early recurrence and poorer survival after curative resection for early stage hepatocellular carcinoma. Sci Rep 2016;6:28229. [PMID: 27320390 DOI: 10.1038/srep28229] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
87 Zhong JH, Yang T, Xiang BD, Li LQ, Ma L. Antiviral therapy for hepatitis B virus-related hepatocellular carcinoma after surgery: A comment for moving forward. World J Hepatol 2016; 8(13): 605-606 [PMID: 27168873 DOI: 10.4254/wjh.v8.i13.605] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
88 Lin XJ, Lao XM, Shi M, Li SP. Changes of HBV DNA After Chemoembolization for Hepatocellular Carcinoma and the Efficacy of Antiviral Treatment. Dig Dis Sci 2016;61:2465-76. [PMID: 27105647 DOI: 10.1007/s10620-016-4167-5] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.7] [Reference Citation Analysis]
89 Chen JL, Lin XJ, Zhou Q, Shi M, Li SP, Lao XM. Association of HBV DNA replication with antiviral treatment outcomes in the patients with early-stage HBV-related hepatocellular carcinoma undergoing curative resection. Chin J Cancer 2016;35:28. [PMID: 26992891 DOI: 10.1186/s40880-016-0089-z] [Cited by in Crossref: 19] [Cited by in F6Publishing: 24] [Article Influence: 3.2] [Reference Citation Analysis]
90 Yuan P, Chen P, Qian Y. Evaluation of Antiviral Therapy Performed after Curative Therapy in Patients with HBV-Related Hepatocellular Carcinoma: An Updated Meta-Analysis. Can J Gastroenterol Hepatol. 2016;2016:5234969. [PMID: 27446846 DOI: 10.1155/2016/5234969] [Cited by in Crossref: 6] [Cited by in F6Publishing: 15] [Article Influence: 1.0] [Reference Citation Analysis]
91 Ayoub WS, Martin P, Lampertico P. Does Nucleos(t)ide (NUC) Analogs Therapy in Hepatitis B Impact the Incidence of Liver Cancer? Curr Hepatology Rep 2015;14:279-283. [DOI: 10.1007/s11901-015-0279-1] [Reference Citation Analysis]
92 Xu L, Wang J, Kim Y, Shuang ZY, Zhang YJ, Lao XM, Li YQ, Chen MS, Pawlik TM, Xia JC. A randomized controlled trial on patients with or without adjuvant autologous cytokine-induced killer cells after curative resection for hepatocellular carcinoma. Oncoimmunology. 2016;5:e1083671. [PMID: 27141337 DOI: 10.1080/2162402x.2015.1083671] [Cited by in Crossref: 34] [Cited by in F6Publishing: 37] [Article Influence: 4.9] [Reference Citation Analysis]
93 Ma SL, Lv Y, Jiang JH. Efficacy of combined adjuvant transarterial chemoembolization and antiviral therapy in patients with HBV-related hepatocellular carcinoma after surgery. Tumour Biol 2015;36:7395-6. [PMID: 26342698 DOI: 10.1007/s13277-015-4026-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
94 Kanda T, Ogasawara S, Chiba T, Haga Y, Omata M, Yokosuka O. Current management of patients with hepatocellular carcinoma. World J Hepatol 2015; 7(15): 1913-1920 [PMID: 26244066 DOI: 10.4254/wjh.v7.i15.1913] [Cited by in Crossref: 32] [Cited by in F6Publishing: 34] [Article Influence: 4.6] [Reference Citation Analysis]
95 Baran B. Nucleos(t)ide analogs in the prevention of hepatitis B virus related hepatocellular carcinoma. World J Hepatol 2015; 7(13): 1742-1754 [PMID: 26167247 DOI: 10.4254/wjh.v7.i13.1742] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 2.4] [Reference Citation Analysis]
96 Russo FP, Rodríguez-Castro K, Scribano L, Gottardo G, Vanin V, Farinati F. Role of antiviral therapy in the natural history of hepatitis B virus-related chronic liver disease. World J Hepatol 2015; 7(8): 1097-1104 [PMID: 26052398 DOI: 10.4254/wjh.v7.i8.1097] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.7] [Reference Citation Analysis]
97 Scientific surgery. British Journal of Surgery 2015;102:861-861. [DOI: 10.1002/bjs.9844] [Reference Citation Analysis]
98 Yim HJ, Suh SJ, Um SH. Current management of hepatocellular carcinoma: An Eastern perspective. World J Gastroenterol 2015; 21(13): 3826-3842 [PMID: 25852267 DOI: 10.3748/wjg.v21.i13.3826] [Cited by in CrossRef: 36] [Cited by in F6Publishing: 39] [Article Influence: 5.1] [Reference Citation Analysis]
99 Zhong JH. Nucleos(t)ide analogue therapy for HBV-related HCC after hepatic resection: clinical benefits and unanswered questions. Tumour Biol. 2014;35:12779-12784. [PMID: 25431264 DOI: 10.1007/s13277-014-2881-1] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 2.1] [Reference Citation Analysis]
100 Ke Y, Wang L, Li LQ, Zhong JH. Nucleos(t)ide analogues to treat hepatitis B virus-related hepatocellular carcinoma after radical resection. World J Hepatol 2014; 6(9): 652-659 [PMID: 25276281 DOI: 10.4254/wjh.v6.i9.652] [Cited by in Crossref: 10] [Cited by in F6Publishing: 13] [Article Influence: 1.3] [Reference Citation Analysis]